Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market Insight
Published: 30 July 2026 | Report Format: Electronic (PDF) | Author: Govind and Krishna
The Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market will grow at a rate of 14.82% due to rising demand for effective diabetes management therapies, increasing prevalence of type 2 diabetes and obesity, expanding geriatric population, and the growing clinical adoption of once-weekly injectable and oral peptide formulations across metabolic care institutions.
Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market Insights Forecasts to 2035
- The Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market Size Was Estimated USD 1,245.8 Million in 2025
- The Market Size is Expected to Grow at a CAGR of around 14.80% from 2025 to 2035
- The Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market Size is Expected to rise around USD 4,952.4 Million by 2035
Notable Insights for the Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market
- Segmentation on the basis of Drug Type indicates that Semaglutide and once-weekly peptide therapeutics dominate Japan market in 2025 with 52% share across metabolic healthcare channels.
- Segmentation on the basis of Application indicates that Type 2 Diabetes Mellitus Treatment segment dominates Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market 2025 with 68% share, driven by clinical reimbursement approvals and glycemic control requirements.
- World-wide projected revenue of Novo Nordisk A/S in fiscal year 2025 would be around $41.5 billion, owing to high demand for GLP-1 receptor agonist therapies, chronic weight management treatments, and diabetes care products.
- It is expected that increasing clinical awareness, lifestyle-related metabolic disorders, and expansion of non-invasive oral peptide administration would contribute in driving the growth of the market, where GLP-1 receptor agonists offer HbA1c target achievement up to 41%, and minimize cardiovascular adverse events up to 22%.
Download the eBook (ToC)
Why Buy This Report
- Gives an in-depth analysis of the impact of trends in metabolic endocrine research, clinical expansion in obesity management, and development in long-acting peptide delivery systems on the Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market growth.
- Provides strategic insights regarding technology innovation such as dual GLP-1/GIP receptor co-agonism, oral SNAC delivery technology, subcutaneous auto-injector innovations, and continuous glucose monitoring integrated digital therapy.
- Assists players to analyze competitive benchmarking, investment in pharmaceutical manufacturing plants, clinical trial expansion in Japanese medical centers, and strategic distribution partnerships by major metabolic pharmaceutical suppliers.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market
- Novo Nordisk A/S
- Eli Lilly and Company
- AstraZeneca plc
- Sanofi S.A.
- Sumitomo Pharma Co., Ltd.
- Takeda Pharmaceutical Company Limited
- Boehringer Ingelheim International GmbH
- Daiichi Sankyo Company, Limited
- Chugai Pharmaceutical Co., Ltd.
- Kyowa Kirin Co., Ltd.
Recent Developments:
- In February 2026, Eli Lilly Japan K.K. received manufacturing and marketing approval from the Ministry of Health, Labour and Welfare (MHLW) for an expanded chronic weight management indication for tirzepatide in adult patients with metabolic comorbidities.
- In September 2025, Novo Nordisk Pharma Ltd. partnered with Chugai Pharmaceutical Co., Ltd. to enhance hospital co-promotion and local distribution network for high-dose oral semaglutide formulations across Japanese regional healthcare facilities.
Market Segmentation:
Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, By Drug Type
- Semaglutide
- Tirzepatide (Dual GLP-1/GIP Agonist)
- Dulaglutide
- Liraglutide
- Exenatide & Other Peptides
Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, By Route of Administration
- Subcutaneous Injections (Once-Weekly / Once-Daily)
- Oral Peptides
- Prefilled Pen Injectors
- Inhaled & Novel Peptide Formulations
- Smart Delivery Systems
Japan Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Market, By Application
- Type 2 Diabetes Mellitus Treatment
- Obesity & Chronic Weight Management
- Cardiovascular Risk Reduction
- Non-Alcoholic Steatohepatitis (NASH/MASH)
- Chronic Kidney & Metabolic Syndrome Management
Expert Views:
The market for glucagon-like peptide-1 (GLP-1) receptor agonists in Japan will grow owing to the rise in the demand for high efficacy glycemic control therapies, the growing number of type 2 diabetes and obesity diagnoses, and increasing demand for oral peptide medications. The inclusion of multi-receptor target mechanisms, next-generation auto-injector pens, and early intervention clinical protocols will enhance therapeutic adherence and boost the demand for GLP-1 receptor agonists in the Japanese market.
Author: Govind and Krishna By Decisions Advisors and Consulting